TY - JOUR
T1 - Targeted therapies in advanced differentiated thyroid cancer
AU - Carneiro, Raquel M.
AU - Carneiro, Benedito A.
AU - Agulnik, Mark
AU - Kopp, Peter A.
AU - Giles, Francis J.
N1 - Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Differentiated thyroid cancer is the most common endocrine malignancy, and its incidence has been rising rapidly over the past 10. years. Although most patients with this disease have an excellent prognosis, a subset develops a more aggressive disease phenotype refractory to conventional therapies. Until recently, there was no effective therapy for these patients. With increasing knowledge of the molecular pathogenesis of thyroid cancer, novel targeted therapies are being developed for this group of patients. Sorafenib and lenvatinib, small-molecule multikinase inhibitors, were approved for the treatment of progressive, symptomatic, radioactive iodine refractory, advanced differentiated thyroid cancer in 2013 and 2015, respectively. This represents a major innovation in the therapy of patients with advanced thyroid cancer. However, these therapies still have many limitations and further research needs to be pursued with the ultimate goal of providing safe and effective personalized therapy for patients with advanced thyroid cancer.
AB - Differentiated thyroid cancer is the most common endocrine malignancy, and its incidence has been rising rapidly over the past 10. years. Although most patients with this disease have an excellent prognosis, a subset develops a more aggressive disease phenotype refractory to conventional therapies. Until recently, there was no effective therapy for these patients. With increasing knowledge of the molecular pathogenesis of thyroid cancer, novel targeted therapies are being developed for this group of patients. Sorafenib and lenvatinib, small-molecule multikinase inhibitors, were approved for the treatment of progressive, symptomatic, radioactive iodine refractory, advanced differentiated thyroid cancer in 2013 and 2015, respectively. This represents a major innovation in the therapy of patients with advanced thyroid cancer. However, these therapies still have many limitations and further research needs to be pursued with the ultimate goal of providing safe and effective personalized therapy for patients with advanced thyroid cancer.
KW - Differentiated thyroid cancer
KW - Follicular thyroid carcinoma
KW - Targeted therapy
KW - Thyroid cancer
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84941024956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941024956&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2015.06.002
DO - 10.1016/j.ctrv.2015.06.002
M3 - Review article
C2 - 26105190
AN - SCOPUS:84941024956
SN - 0305-7372
VL - 41
SP - 690
EP - 698
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
IS - 8
ER -
